Drug comparisons
Sotagliflozin vs Troglitazone
Compare Sotagliflozin (Inpefa) dual SGLT1/2 inhibitor vs Troglitazone withdrawn TZD for diabetes. Differences in CV benefits, liver safety, and use.
No comparison dimensions are available for this page.
Clinical context
This comparison is triggered when evaluating discontinued thiazolidinediones against current dual SGLT inhibitors for type 2 diabetes and cardiovascular risk.
Bottom line
Sotagliflozin is the available dual SGLT inhibitor option, unlike withdrawn Troglitazone which carried unacceptable liver risks.
All medication comparisons